


Veeda Clinical Research & Shimadzu collaborate to explore new avenues in Mass Spectrometry applications for clinical research

25 August 2016 | News | By BioSpectrum Bureau

Veeda Clinical Research & Shimadzu collaborate to explore new avenues in Mass Spectrometry applications for clinical research



Shimadzu (Asia Pacific) Pte Ltd, Singapore, a global leader in analytical instruments and Veeda Clinical Research Pvt Ltd, Ahmedabad, India, one of India's foremost player in the CRO industry, have signed a Memorandum of Understanding (MoU) to collaborate in the areas of clinical research involving mass spectrometers.

This collaboration will see the development of new analytical methods and also lead to improvement in the existing protocols or methods that are used in BA/BE studies under a regulatory-compliant environment. Veeda's laboratories will function as a Partner- Laboratory in India for Shimadzu in this segment. The agreement was signed at Chennai on the occasion of the inauguration of Spinco Towers, Chennai on August 22, 2016.

The partnership heralds a new beginning by enabling studies using 'high sensitivity mass spectrometers' in the field of clinical research, which has seen rapid progress during the last decade. As the need for the ultra-high sensitivity mass spectrometry instruments, to measure drug candidates in various clinical subjects during the trials, is ever-increasing, this collaboration opens up new opportunities to devise unique solutions for solving analytical challenges. This will certainly contribute to an accelerated drug development process.

Apurva Shah, Group Managing Director, Veeda Clinical Research Pvt Ltd, India, outlined that the cooperation is a significant milestone in Veeda's journey to advance clinical trials to much greater levels of performance. He further said, "Shimadzu's newly launched 'world's highest sensitivity LCMS-8060 triple quadrupole mass spectrometers' are an ideal platform for the ultra-high sensitivity analysis of the drugs and their metabolites in the clinical subjects. The system allows development of superior methods for the detection and quantitation of drugs and their metabolites in complex clinical samples."

Also read: Biosimulation market size to reach \$3.77 bn by 2024

Teruhisa Ueda, President & Chief Executive Officer of Shimadzu Corporation, Japan, who was present during the occasion, appreciated the world-class infrastructure created at the multiple laboratories of Veeda Clinical Research. Dr Ueda said that through this agreement, Shimadzu would significantly gain deeper insights in bioanalysis for clinical trials using mass spectrometry.

Kiminobu Imura, Managing Director, Shimadzu (Asia Pacific) Pte Ltd, Singapore, who signed the agreement on behalf of Shimadzu, reiterated that his team will extend the maximum support to this initiative both directly and also through their Indian distributor Spinco Biotech, with whom they have had a successful partnership for 33 years.